The U.S. Food and Drug Administration (FDA) has issued a formal announcement stating that it will hold a Pharmacy Compounding Advisory Committee meeting on July 23 and 24. During this meeting, officials will evaluate various bulk drug compounds related to peptides to determine whether they should be included in the 503A bulk drug list. This process marks a milestone in the preliminary procedure rather than a direct regulatory approval.
Investor sentiment has been further boosted by RFK Jr.'s public statement regarding potential changes in FDA regulatory policies. The FDA is considering lifting restrictions on up to 12 different peptides, with the evaluation process expected to continue until February 2027.
Bank of America Raises Price Target
In light of this regulatory development, Bank of America Securities has raised HIMS's price target from $21 to $25, although the company maintains a neutral investment rating. This adjustment reflects an increase in valuation multiples, now approximately 25.5 times, up from 21.5 times, primarily due to rising multiples of peer companies and emerging peptide opportunities.
The investment firm remains cautious about this announcement. Analysts described the news as a "preliminary small step" and stated that unless the FDA makes a formal decision, no direct impact on earnings forecasts is expected.
The regulatory agency also emphasized that most of the compounds under evaluation still pose potential safety concerns under the existing guidance framework.
Latest Developments at HIMS
The telehealth platform has recently expanded its product line to include FDA-authorized GLP-1 treatment products from Novo Nordisk, which feature both injectable and oral forms of Wegovy. The oral version of Wegovy is the only FDA-approved GLP-1 weight management drug on the market.
Additionally, the platform provides access to Ozempic injection pens, although these products are only approved for the management of type 2 diabetes.
The competition in the GLP-1 market is intensifying. Amazon Pharmacy recently launched Eli Lilly's newly approved GLP-1 drug Foundayo, offering same-day delivery services, which increases competitive pressure on Novo Nordisk and HIMS.
Regarding insider trading, Chief Financial Officer Oluyemi Okupe filed to sell approximately $4.9 million in shares. Over the past quarter, company insiders have collectively sold about $3.4 million in stock, with no recorded insider buying activity.
HIMS currently has a price-to-earnings ratio between 45 and 47 times. According to InvestingPro's valuation analysis, HIMS's stock appears overvalued compared to fair value calculations. The telehealth company has a market capitalization of approximately $5.54 billion, serving over 2 million users.
Bank of America's EBITDA forecast for 2026 is approximately 21% lower than the Wall Street consensus.